Organization
Johnson & Johnson Innovative Medicine Research & Development
1 abstract
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,